Kejriwal inspects 10k-bed Pvt labs say new rates may impact Chhatarpur Covid facility testing capacity, won’t cover costs
nNEW DELHI: Delhi chief minister Arvind Kejriwal on Thursday visited the Radhasoami Satsang Beas in south Delhi’s Chhatarpur, where the government is setting up a makeshift Covid-19 health care facility with 10,000 beds over an area big enough to cover 20 football fields.
For this facility, the Delhi Disaster Management Authority (DDMA) has urged the central government to allow the Army and central security forces to provide around 2,000 health care officials, largely including doctors and nurses, said a senior government official who did not wish to be identified.
“This 10,000-bed facility should be ready for admission of Covid patients by the first week of July. It will primarily cater to patients with mild or no symptoms who cannot be assigned home quarantine for some reason and may need medical intervention. It will be our biggest dedicated Covid health centre,” Kejriwal said during his visit to the premises, where he was accompanied by deputy chief minister Manish Sisodia.
He said, “By June 30, we shall have 15,000 hospital beds available and the number will go up to 30,000 by July 15. The progress in the health care augmentation exercise is at par with what was planned. Right now, we are focussing more on augmenting ICU beds in hospitals for the coming days.”
On Sunday, Lieutenant Governor Anil Baijal, who heads the DDMA, had visited the site and directed the district administration to file a feasibility report.
A senior official in the revenue department said, the facility – set up on a field that measures around 11.90 lakh square feet — would operate in two shifts and it would need at least 600 doctors and 1,200 nurses, other than workers engaged in waste management, sanitation employees, guards, workers involved in help desks and other back-end operations.
The government is also working on a centralised air conditioning system for the facility, which will be treated like 20 hospitals of 500 bed each, having enclosures that accommodate 100 beds each, said a senior revenue department official, citing the feasibility report filed by the district administration.
nNEWDELHI: The capping of coronavirus disease (Covid-19) testing price at ₹2,400 may lead to fewer samples being tested at private labs because it does not cover the costs, owners of private labs said on Thursday, requesting anonymity.
The Delhi Disaster Management Authority (DDMA) on Thursday approved capping of the rates for all Covid-19 tests, including by private firms at ₹2,400. An expert panel constituted by Union home minister Amit Shah on June 14 did not recommend revising the prices for tests conducted by private labs in Delhi. It only recommended reducing the rates of for the samples collected by the government for private labs.
Until now, the cost of a Covid-19 test was ₹4,500 if the private labs collected the sample and used their own kits, ₹3,500 if the government collected the samples and the private labs used their kits to test it; and ₹2,200 if the government collected the sample and provided the test kit as well.
“Two important things happened today. Covid-19 testing rates in Delhi have been reduced to Rs 2,400 and rapid-antigen testing has started. I hope people won’t face any problem in getting themselves tested now,” Chief Minister Arvind Kejriwal said in a tweet.
Owners of the private laboratories said that the price fixed by the government would not cover their money spent on collection of samples from door-to-door, transportation and the protective gear, etc.
“It is not just the cost of the process of testing, lifting samples from door-to-door incurs ancillary costs that inflates the overall testing price. We could have managed the tests for government collected samples in Rs 2,400, since we won’t have to spend on a personal protection equipment, viral transport medium, swab sticks and transportation. But going home-to-home for collecting samples, spending on manpower and transport and providing protective gear cannot be managed for the same price,” said one of the private lab representatives, requesting anonymity.
“These are costs that the government does not seem to have considered while fixing the price. It will be difficult for a lot of us to sustain this price structure, which would obviously affect the number of samples lifted per day for testing in the long run, especially those from home,” the person added.
Another laboratory representative agreed that home collection of samples cannot be done for such a low price. He said the will have to consider differential pricing, like the one currently in place in Delhi.
“The cost for testing a sample collected by Delhi government is low but for the ones that we collect from the homes we charge ₹4,500. Going below that will hurt our pocket. Plus, if the government wants us to expand our testing capacity, we need to be able to recover money for the additional machines and manpower,” said the second laboratory representative.
Private hospitals testing Covid-19 samples shared similar concerns.
“We are not talking about making profit but we cannot suffer losses. The way prices stand as of now, we are staring at losses. How are we supposed to enhance the testing capacity that everyone seems to be looking at; where is the ability to invest in expensive machinery if there are mounting losses. A gene expert machine testing kit, which is a quicker alternative to RT-PCR testing, costs about ₹2,350 on discount, then how do you expect the test to be conducted at ₹2,400. There is a turnaround deadline of 48 hours so at the end we will be forced to drop the number of samples being tested per day,” said a representative for a prominent hospital, requesting anonymity.
The Delhi government said the decision was taken to help people who had to pay “exorbitant sums of money for tests and treatment”. “The Delhi government reduced the prices because the people have to pay exorbitant sums to get Covid tests done. Also, when other states have capped it, nothing stops Delhi from doing the same. It is what the Centre and the ICMR also have recommended,” said a Delhi government spokesperson.
The Indian Council of Medical Research (ICMR) on Monday recommended use of antigen based testing kits for diagnosis that is likely to bring down the cost of testing. However, hospitals say the kit is not readily available in market yet. “Where are the kits, and what is the price for testing using antigen based kits. There is no clarity even on serology (antibody) test that ICMR also recently recommended. Are we allowed to do those tests? There is utter confusion over it,” said another representative of a prominent hospital in the Capital.